Download - Lundbeck

LUNDBECK
MAGAZINE
09

LUNDBECK
MAGAZINE
09
p6
On behalf
of the brain
p10
Now I dare myself to
leave the house again

3
Blood reveals psychiatric disorders 14
Close to her heart 16
Hoping for a lifebelt 20
A laptop and a vacuum flask 26
Danish-Japanese partnership – the American way 32
In search of building blocks for the future 34
Always one step ahead 36
From genes to galaxies 40
p22
A job
for specialists
p28
A career
with global focus
H. Lundbeck A/S
Corporate Reporting
Design: Bysted A/S
Illustrations: Mads Berg
PRINT: Quickly Tryk A/S
TExT: Xenia Wieth: On behalf of the brain, A job for specialists, From genes to galaxies, A laptop and a vacuum
flask, Blood reveals psychiatric disorders, Danish-Japanese partnership – the American way, In search of
building blocks for the future, Now I dare myself to leave the house again.
Elisabeth Poulsen: Close to her heart, A career with global focus, Always one step ahead, Hoping for a lifebelt.

specialister s22
Lundbeck Magazine 2009
5
Worth
fighting for
We have made it our ambition to be the company that
makes the biggest difference worldwide in the treatment
of patients suffering from brain disorders
rain disorders such as depression,
schizophrenia and Alzheimer’s
disease, to name but a few, inflict
a huge amount of suffering on patients, as
well as sorrow and despair on their relatives.
Hundreds of millions of people in the world
suffer from brain disorders. In spite of
therapeutic progress, unfortunately, we remain
a long way from fully understanding these
disorders. There are immense unmet needs,
not only for medication, but also for entire
solutions in which therapy and updated
information about the disorders are crucial
factors.
Unfortunately, public awareness and the resources
spent on curing and alleviating brain disorders are
a long way from matching the severity and
consequences of these disorders. Brain disorders
place an enormous economic burden on society
because they reduce or eliminate the patient’s
ability to work.
At Lundbeck, we have made it our ambition
to be the company that makes the biggest difference
worldwide in the treatment of patients suffering
from brain disorders. Assuming this responsibility
is an enormous task, but it is also an incredible
joy when we succeed in developing a new and
innovative drug that benefits people worldwide.
In this magazine, we present a cross section of
our world. I hope you will find it a pleasure to
read, and that it will provide insight into who
we are and what Lundbeck stands for.
Yours sincerely
Ulf Wiinberg
President & CEO
PHOTO: Simon ladefoged

Lundbeck Magazine 2009
7
On behalf
of the brain
Throughout his career, Professor Jes Olesen has been
championing the cause of more research in the diseases
which are the most expensive to treat, and which have the
most severe consequences for patients: brain diseases.
The costs of brain diseases are as expensive for
society as the combined costs of heart disease
and cancer, not to mention the enormous
suffering and poor quality of life experienced
by the individual with a brain disease. Despite
the fact that the figures have long since been
documented, brain diseases remain at the back
of the queue for money and attention.
“The brain and the diseases that affect it have
a huge image problem. In contrast to the heart,
for example, it is not possible to feel one’s
brain, despite the fact that the brain is the seat
of the emotions which are traditionally
ascribed to the heart, such as love and sorrow.
The brain is responsible for everything that
makes us human beings; it just has an
incredibly bad press.”
These are the words of a man who for decades
has been struggling for the brain and brain
diseases to be given attention corresponding
to the burden they comprise for both the
individual and society as a whole. Jes Olesen is
a professor of Neurology, and is employed at
the Glostrup Hospital in Copenhagen. His
research has helped to clarify the mechanisms
of migraine headache, and the fact that
Glostrup Hospital is the world’s leading centre
for research in headache is largely due to Jes
Olesen’s efforts.
Enormous need
Jes Olesen is also the man behind the founding
of the European Brain Council (EBC), an
umbrella organization for scientific medical
"The brain is responsible for everything
that makes us human beings; it just has
an incredibly bad press"
societies, patient associations, basic
neurological research and industry. EBC
focuses on brain diseases including psychiatry,
neurology and neurosurgery. Founded in 2002,
the mission of the EBC is ‘to promote brain
research in Europe and to improve the quality
of life of those affected by brain diseases’. In
Europe, 127 million persons have a brain
disease, and the EBC endeavours to improve
these persons’ situation through concentrating
the collective efforts of scientists and laymen
from this very wide field.
“Several branches of medical science and
many patient associations focus on brain
diseases. There is very little tradition for
collaboration between the individual branches.
This is true all over Europe, not just in
Denmark. It is a major problem in relation to
being heard, as well as in relation to obtaining
funds for research and treatment. And the
need is enormous. Brain diseases comprise
one-third of all illnesses, though if one
considers the impact on the lives of individuals
in terms of reduced working ability and quality
of life, brain diseases are responsible for half of
the burden which must be borne by society,”
Jes Olesen states.
PHOTO: Joachim ladefoged

8
Lundbeck Magazine 2009
"Health research is one of
the most profitable activities
a society can invest in"
The European Brain Council
The European Brain Council (EBC) is a
coordinating council formed by European
organizations in neurology, neurosurgery,
psychiatry, basic brain research
(neuroscience), as well as patient
organisations and industry. The EBC
was founded in 2002 in Brussels, and
has offices in Brussels and Florence.
www.europeanbraincouncil.org
No public money for research
Brain diseases are also costly for society. In
fact, they cost as much as heart disease and
cancer put together. In 2004, the cost of brain
diseases in Europe was EUR 386 billion.
“The figure comes from a study that I was
involved in compiling. It revealed that brain
diseases are both more expensive and have
more far-reaching consequences than was
previously thought. But if one looks at the
amount of money that is actually used on
brain research, it is as if this is forgotten.
Migraine, which I specialize in, is a very
expensive disease in socio-economic terms.
It costs European countries EUR 27 billion
annually, but there is almost no public money
to research it. Among the more than 300 PhD
scholarships recently awarded by the Danish
Agency for Science, Technology and
Innovation, there was not one single
scholarship for brain research in Copenhagen.
As a field of study, the brain is not nearly as
prominent as it ought to be,” Jes Olesen says.
High return on investment
However, the EU Commission has in its
Seventh Framework Programme given priority
to brain research for the first time ever.
“This is better than it has been, but I am
disappointed that the strong wording has not
resulted in a similar increase in funds. Health
research is one of the most profitable activities
a society can invest in, and it gives an
enormously high return on investment,” adds
Jes Olesen.
Another problem is the lack of large and
powerful patient organizations on a par with
the Heart Association or the Cancer Society.
“The area of brain diseases is poorly organized.
In Denmark, we have 27 patient organizations
that focus on brain-related issues, but there is
a lack of collaboration between them and
affected persons to lead out in efforts on
behalf of the cause. Persons who have been
cured of heart disease or cancer are frequently
so grateful that they become involved in
volunteer activities – and have the strength
to do so. But no one wishes to step forward on
the basis of a psychiatric diagnosis. In addition,
brain diseases sap patients of their energy to
the point where they must draw on their
meagre reserves,” Jes Olesen explains.
On the rise
And the need for more knowledge and
treatment will continue to rise. Brain diseases
do not merely disappear. Dementia and
migraine are both on the rise in the Western
world, while the situation for psychiatric
diseases is less clear. The only disease in which
progress with certainty is being made is stroke.
“That there are more persons with dementia is
related to the fact that more people are living
longer. But we have no idea why the incidence
of migraine headache is rising. That the
incidence of stroke is not rising by five per
cent annually as statistics indicate it should, is
probably due to better prevention in the form
of medications that lower blood pressure and
inhibit cholesterol formation. And also that we
have become better at warning people to
avoid alcohol and tobacco, or at least to keep
down their consumption, which is also true in
relation to some other brain diseases. Apart
from that, the prevention of brain diseases is
largely uninvestigated,” Jes Olesen says.
PHOTO: Joachim ladefoged

10
"The psychiatrist offered
me medication, but I didn’t
want it. I was only 17 at
the time"

Lundbeck Magazine 2009
11
Now I dare myself to
leave the house again
Yolanda has suffered from depression since she was very
young. But only now is she receiving the treatment that helps.
Yolanda is 52 years of age and lives in Mexico
City. She is the mother of three, and together
with her husband she operates a small
company that sells natural medicine.
Yolanda was only a teenager when she had
depression for the first time. At the time, she
decided that she would manage without help
– and certainly without medication.
“I didn’t know any better, and for many years
things went fairly well. But when my youngest
son became ill, I went into severe depression,”
Yolanda recounts. Her son was 16 years old
when he began behaving violently towards the
family.
“It was especially towards his father and
brother. I was the only one who could approach
him. It culminated one day when he attempted
to stab his father with a knife. We drove him to a
psychiatric hospital where I knew some doctors.
They discovered that our son had schizophrenia
and kept him in hospital for a month. He had
been aggressive ever since he was a small child,
but we didn’t know why. We just thought he was
a bit different,” Yolanda says.
PHOTO: Joachim ladefoged

Lundbeck Magazine 2009
13
"I have depression and I
am being treated for it"
A long way to go
Their son received treatment and began
attending school again. And then his mother
collapsed.
“I refused to get up; I would not leave the
house; I wept much of the time and felt utterly
desolate. And I didn’t know what was wrong.
I have always been a very strong and
independent woman. Here in Mexico, women
are responsible for the home, and we believe
we can cope with anything. My husband said
joking that, ‘it’s just not possible for you to get
ill, because there’s no one to take care of you
and the house.’ He could scarcely even
recognize me,” Yolanda says.
Her depression had returned and was worse
than ever. She was admitted to hospital where
her doctors succeeded in convincing her that
she needed medication, and Yolanda has now
been in treatment for approximately 18
months. She is taking antidepressants and goes
to therapy several times a week.
“Now I am making progress. It is slow, I have a
long way to go, and it is very hard work. Some
days, life is both sad and painful, but I get up in
the morning and do my work. And I dare
myself to walk alone in the street again,”
Yolanda says with a slight smile.
Harsh childhood
Yolanda’s son’s schizophrenia is not the only
gloomy chapter in her life. Her story is a tale
of a harsh childhood in one of the poor
districts of Mexico City; a tale of abuse and
repeated rapes, one of which resulted in her
becoming pregnant at the age of 16.
“I was determined to get out of that
environment, and took a short secretarial
course. When I became pregnant, I had to find
a job to support myself and the child. I got a
job with an art gallery, and the lady who
owned it arranged for me to have therapy. The
psychiatrist offered me medication as well, but
I didn’t want it. I was only 17 at the time,”
Yolanda continues.
Felt a sense of guilt
Later, she married and had two more children,
even though she didn’t want to at the time.
“Being raped had filled me with fear, and it was
very difficult for me to care for my children.
Merely touching them filled me with anxiety.
When my youngest son became ill, I felt a
terrible sense of guilt. I felt that it was my fault
that he had schizophrenia. And that seriously
exacerbated my depression,” Yolanda says.
She now wishes that she had accepted the
medication she was offered by doctors many
years ago, and that people were better
informed about psychiatric disorders.
“When people say that I am neurotic or crazy,
I reply that I have depression and that I am
being treated for it. If people were better
informed about psychiatric disorders, the
world would look a lot different,” says Yolanda.
FOTO: Joachim ladefoged

14
Blood reveals
psychiatric disorders
Lundbeck researchers seek new knowledge of depression
biology in patient blood samples.

Lundbeck Magazine 2009
15
You go to the doctor, have a blood sample
taken, and the result reveals if you are
predisposed for developing depression later in
your life. While this may sound like science
fiction, it may not be many years before it
becomes reality. Scientists at Lundbeck
Research USA in New Jersey are working
towards a new means of diagnosing and
treating depression, anxiety and a number of
other brain disorders.
“We are seeking to understand the basic
mechanisms of depression with the aid of
blood samples from patients who are receiving
medical treatment,” says Irina Antonijevic,
Psychiatrist and Director Translational Research
at Lundbeck Research USA.
Biomarkers in the blood
“We observe how the medication affects
specific biomarkers. We use this knowledge to
attempt to understand the biology of the
disorder, to enable us in future to develop
better and more specific methods of treatment.
At present, most patients with depression
receive more or less the same treatment, which
is not necessarily a good idea. There are simply
no alternatives,” Irina states.
Using biomarkers to clarify if a specific drug will
benefit a specific patient is a new and groundbreaking
view of treatment. Irina and her
colleagues in both New Jersey and Valby
primarily study biomarkers in the blood.
“We are doing this, because blood samples
are easy to obtain, and because there are
standardized methods of preserving and
measuring the messenger RNA (mRNA)
content in blood. mRNA is an intermediate
cellular product in the ‘translation’ of the
genetic code into proteins, which is what we
are studying in blood cells. It is still widely
maintained that a disorder such as depression
cannot be traced in the blood, but how do we
know that? Depression clearly takes place in
the brain, but then blood does flow through the
brain,” Irina continues.
High time
“It is our theory that some critical changes we
can measure in the blood also take place in the
brain. We have begun using the method on
blood samples from patients, and can already
see different patterns in different groups of
patients who all have depression or anxiety.
Now we will attempt to find out if we can
predict how patients with a specific mRNA
profile will react to a specific treatment,” Irina
explains.
The hope is that it will someday be possible to
predict which medication will work best on the
individual patient on the basis of disease
biology.
“And it is high time that this happens. Doctors
in the CNS field are now using substances that
are based on discoveries made by sheer good
luck. In some areas we have made very little
progress during the last 50 years. The most we
have done is to find medicines with fewer side
effects. As a psychiatrist with many years of
experience, it can make me very angry indeed
when I consider the fact that we have no idea
who will benefit from a drug and who will not,”
Irina says.
"What would make me happiest would
be a totally new concept for a drug for
treatment of a psychiatric disorder"
Farewell to diagnoses
She also hopes that the new knowledge will put
an end to the current classification of diagnoses
which, in her view, are both too general and too
crude.
“My dream is to change the whole system
entirely, so biomarkers are used to diagnose
patients. And that patients with the same
biological deviation are treated in the same way,
regardless of the diagnosis we may have given
them. I would like to expand biomarker methods
to include diagnosis of Alzheimer’s disease and
schizophrenia and other CNS disorders. It is
possible that the mRNA profiles of some
patients with schizophrenia will resemble those
of some patients who have depression. It may
even prove to be possible to intervene with
treatment when the first symptoms occur and
prevent the disorder from developing, because it
can be traced early on in the blood. We know
that many adults who have depression have had
anxiety as children or teenagers, and much
evidence indicates that many brain disorders
begin much earlier than has hitherto been
thought.”
From the clinic to the laboratory
The work with biomarkers is also a step on the
road towards translational medicine (TM), a
concept which is currently high on the agenda
of the pharmaceutical industry. TM involves
transferring knowledge from work with patients
in the clinical setting to cell and animal models
in the laboratory.
“We will use the information from patient’s
blood in animal models, and study if the same
biological changes take place in the animal. With
time, this will give us a far better understanding
of the mechanisms of the disorder we wish to
treat. What would make me happiest would be a
totally new concept for a drug for treatment of
a psychiatric disorder: one that was developed
on the basis of biological data from start to
finish. Perhaps it will one day be possible to
predict the risk of individuals developing
depression and other CNS disorders and diseases
on the basis of merely a blood sample. That
would be wonderful,” says Irina Antonijevic.
PHOTO: Joachim ladefoged

16 Lundbeck Magazine 2009
Close to
her heart
The ratio of elderly persons in China is rising rapidly, and 30
years from now the country will have as many persons with
dementia as in the entire rest of the developed world.
Professor Zhang Zhen-Xin is one of China’s
leading neurologists who specialize in
Alzheimer’s and Parkinson’s disease. As a
professor at Beijing Union Medical College
Hospital, she has studied Alzheimer’s untiringly
for more than 40 years. She feels that it is her
responsibility to increase knowledge and
awareness of the disease as well as the
treatment for it. Because Professor Zhang is
convinced that treating Alzheimer’s is
definitely worth while.
“I have patients who have been treated for
more than 10 years, and who with the aid of
medicine can still communicate and perform
daily tasks when they have the right help,”
Zhang Zhen-Xin says. As adviser to the Chinese
health authority SFDA, she is also one of the
leading experts in the newly-established
Lundbeck Institute in China.
“China has a rapidly aging population. Thirty
years from now, the country will have just as
many persons with dementia as there are in
the entire rest of the developed world. Our
government is aware of the problem, which is
sometimes referred to as a ticking bomb,” says
Professor Zhang.
“Parkinson’s has been in focus for some time,”
she adds, “because several of our political
leaders – including Deng Xiao-Ping – had the
disease. But it was commonly thought that the
incidence of Alzheimer’s was significantly
lower in China than in the rest of the world.”
5.8 per cent have Alzheimer’s
Zhang Zhen-Xin helped disprove the myth
when she headed an epidemiological study of
the incidence of dementia in a number of
cities and rural areas in China. The study, which
took six years and included 40,000 persons, is
one of the most comprehensive in the world,
and clearly showed that the incidence of
dementia in China is on a par with that in the
rest of the world’s population. The study shows
that 5.8 per cent of the population above the
age of 65 develop Alzheimer’s.
“Dementia and Alzheimer’s used to be
considered a natural result of old age. And
even now, very few are diagnosed or treated
for the disease by a doctor. This is changing,
however. Especially in wealthy cities such as
Shanghai, the ratio of persons who seek
treatment is on the rise. And this despite the
fact that most people have to pay every yuan
themselves. There is no government
reimbursement for medication for dementia.”
China has a long tradition in herbal medicine.
And while professor Zhang does not dismiss
traditional medicine across the board, she does
believe it is often fraudulent when elderly
persons pay thousands of yuan for a small
amount of herbal medicine. And she
underscores the fact that most Chinese
consumers now prefer Western
pharmaceuticals, of whose efficacy has been
scientifically established.
Sons care for their parents
Zhang Zhen-Xin spent time in rural areas
where she literally went from bed to bed
visiting patients during the course of one of
her studies in the late 1990s.
“Conditions were often deplorable. In China,
the sons traditionally care for their parents. If
there are several sons, they care for their
parents in turn. Especially in poor rural areas,
however, there is little sympathy for persons
with dementia, and they risk being turned out
if caring for them becomes too difficult.
Persons with dementia often die within a few
years due to malnutrition, pneumonia and
poor care.”
“This situation has improved, especially among
well-educated people in the cities – first and
foremost due to the improved economy. The
PHOTO: Simon ladefoged

"It is not true when
people say that there is
no treatment for
Alzheimer’s disease,
because there is"
17

Lundbeck Magazine 2009
19
health system is also being expanded, though
at present only highly-placed government
employees have full coverage. The rural
population has no coverage whatsoever, but
political initiatives have now been taken to
provide a certain amount of health insurance
coverage for agricultural labourers.”
“Nursing homes are now also available,
especially in the cities, but they are expensive.
People who can afford to do so, employ a
person to care for their parents. An example of
this would be modern families who are fully
occupied by their work,” Zhang says, adding
that the one-child policy makes it increasingly
essential for the government to solve the
problem of the rising numbers of elderly
persons with dementia. The care burden is
simply becoming too great.
An important role for Lundbeck
The task of getting government authorities to
provide support for treatment of dementia in
future is very close to Professor Zhang’s heart.
The same is true of increasing knowledge and
awareness of the disease among doctors,
families and friends.
“The Lundbeck Institute plays an important
role in that respect. Its activities will enable us
together to spread knowledge of the disease
and treatment for it to doctors throughout
China. I am very impressed by Lundbeck –
particularly by the fact that the company does
not think merely in terms of commercial
interests – but has a long-term view to
improving quality of life for patients, as well
as their family and friends. Doctors and the
pharmaceutical industry have many common
interests. And we can help a lot of people by
working together,” Zhang Zhen-Xin states. She
has also received support for her research from
Lundbeck.
In addition to looking after her patients at
Beijing Union Medical College Hospital, she
is an untiring lecturer and instructor – not just
in China, but also at the international level
where her comprehensive knowledge is highly
respected.
The same is true among her patients. On
display in her office, one can see several gifts
from grateful patients whom she has treated
for Alzheimer’s. “Thank you for adding a year
to my life,” says one of the New Year’s
greetings she has received.
“And that warms my heart,” Professor Zhang
says.
“It is not true when people say that there
is no treatment for Alzheimer’s disease,”
she adds, “because there is. We only have
to persevere in making government officials
and the general public aware of the fact that
treating Alzheimer’s is truly worth while.
We can make a difference.”
New Lundbeck Institute in China
In December 2008, Lundbeck opened
The Lundbeck Institute, China. Based in
Beijing, the Institute will work to spread
knowledge of CNS disorders among
doctors and patient associations in China.
The aim is to contribute to improving
quality of life for persons with psychiatric
or neurological disorders.
Like The Lundbeck Institute in Denmark,
the Institute in China will help establish
the Lundbeck name as a research-based
company that specializes in CNS. The
Lundbeck Institute in Denmark has
held courses on depression, anxiety,
schizophrenia and dementia for more
than 4000 specialists from around the
world since it was founded.
The Institute in Beijing intends to hold
courses for Chinese specialists conducted
by specialists from China. The newly
established Institute has therefore allied
itself with a number of key opinion
leaders in the fields of psychiatry and
neurology.
PHOTO: Simon ladefoged

20 Lundbeck Magazine 2009
Hoping
for a lifebelt
Mehmet Cengiz has had Parkinson’s disease for six years. His
health condition has gradually worsened, and his hopes are now
pinned on scientists discovering a new drug for the disease.
Mehmet Cengiz’s face lights up despite his
serious condition when he speaks of his hope
in the progress of research in Parkinson’s
disease. He became ill six years ago, and now,
at the age of 48, his illness has progressed to
a stage that occasionally makes it difficult for
him to walk and speak. He still works, but as
the disease progresses, working is becoming
more and more difficult. He no longer dares
to make plans for the future, but is still
hoping that scientists will discover new
medications and new forms of treatment that
can combat the disease and improve his
quality of life. This is one of the things that
keep him going.
Dropped the salt
It all began six years ago with a tingling in his
left arm.
“I dropped the salt I had in my fingers, and my
friends asked why I held my left arm against
my body in such a strange way,” Mehmet
Cengiz recalls, sitting at home in his flat in
Istanbul. He thought that a nerve in his arm
had been damaged.
But there was nothing wrong with his nerves.
Instead, a doctor asked him if he had ever
heard of Parkinson’s disease.
“I had no idea what it was, and I was shocked
when I was given the diagnosis. It is difficult and
very alarming to learn that one has a chronic
and incurable disease.” Mehmet Cengiz says.
At home, he began searching the Internet to find
out more about the disease, and discovered that
he was far from alone. Among famous
Parkinson’s patients, he discovered names such
as Pope John Paul II, Bülent Ecevit,the former
Prime Minister of Turkey, the actor Michael J.
Fox, and the boxer Muhammad Ali.
Involuntary isolation
Even though he shares the diagnosis with
approximately 0.2 per cent of the population in
Turkey and the rest of the world, his illness has
still sent him into a form of involuntary
isolation. He used to travel frequently and often
spent time with friends and family. But he rarely
goes out anymore, primarily because he
sometimes has difficulty walking and speaking,
and easily becomes tired. But also because he
feels that people stare at him.
In addition to decreased mobility and tremors in
the hands, another typical symptom is loss of
facial expression. This means that others have
difficulty in interpreting the expressions on one’s
face, and sometimes think that one is displeased
or angry when this is not at all the case.
“My family have grown accustomed to it, but it
is more difficult with friends and acquaintances.
I still feel that they stare at me,” Mehmet Cengiz
says. For this reason, he prefers to stay at home
in the flat with his wife and daughter.
“It would be good if ordinary people knew more
about Parkinson’s disease. I am continually asked
to explain what Parkinson’s disease is, and I
don’t always feel like doing it or have the energy
to do so,” he says. Parkinson’s patients in Turkey
do not yet have an association that can help
spread knowledge of the disease.
Recently, however, Mehmet Cengiz has improved
a great deal, due to a new combination of
medicine. This has given him the courage to go
out again and to get some exercise. His wife has
also given up her job so she can help him in his
store where he sells electric cables.
“My neurologist could hardly believe her eyes
when she saw me a few days ago,” Mehmet
Cengiz recalls with satisfaction in his voice.
Medically, he feels that he is in good hands, and
the national health system also pays for his
medicine.
So, even though he takes one day at a time, the
new treatment has given Mehmet Cengiz a ray
of hope for himself and for the future.
PHOTO: Simon ladefoged

"For me, any new form of
treatment would be like getting
a lifebelt in a storm at sea"
21

Lundbeck Magazine 2009
23
A job
for specialists
Professor Markku Kaste has placed Finland among the
world’s leading nations in treatment of stroke.
No one wants to suffer a stroke. But if
Professor Markku Kaste were to have one, he
knows where he would want to be treated: in
Finland.
Here, it was recognized 30 years ago that
stroke requires treatment by specialists.
Finnish stroke patients are therefore always
sent to the nearest large hospital that has
expertise in neurology. Hospitals with
neurological expertise are the only places that
have the broad professional basis necessary for
providing optimal treatment. When a resident
of Helsinki suffers a stroke – and there are
approximately 2000 incidences of stroke
annually in the Finnish capital – the special
neurological emergency room and the acute
stroke unit at Helsinki University Central
Hospital, HUCH, in Meilahti where Markku
Kaste works – is ready and waiting when the
ambulance arrives.
Call centre 112 and ambulance personnel are
trained to recognize the symptoms so they are
able to alert the stroke team to be prepared,
and the patient is met by a stroke neurologist,
a stroke nurse and a laboratory technician as it
enters the doors to the hospital. The laboratory
technician is ready to take blood samples, and
following a quick neurological examination,
Facts about stroke Stroke is an acute bleeding (hemorrhagic stroke) or blood clot in the brain artery
(ischemic stroke). In ischemic stroke the supply of oxygen to an area of the brain fails, and the brain
cells die. Depending where in the brain the damage takes place, one’s capability to move one’s arm
and leg can be lost on the opposite side of the body. If the centres that control speech and language
are affected, one can lose the ability to speak and to understand language.
Stroke is the most frequent cause of permanent invalidity in both Europe and the United States. At the
global level, stroke is currently the second-most frequent cause of death, and the number of people
affected by stroke is rising as population is aging, and the risk of suffering a stroke increases with age.
the patient is placed in a CT scanner, and in
which the patient’s name has already been
entered following a prehospital warning call
made by the ambulance personnel. When
appropriate, the patient is treated with a drug
that dissolves the blood clot in the brain artery
immediately after being scanned.
City council saw the light
Rapid and competent intervention is vital if a
patient is to survive and return home or in a
nursing home when treatment is finished. The
credit for Finland’s stroke alert must be given
to Markku Kaste. As a specialist in neurology,
he has for years been fighting for optimal
treatment for everyone who suffers a stroke –
also patients in the scarcely populated areas of
the country.
“Until a task force of the National Board of
Health in 1989 recommended that all stroke
patients should be treated by neurologists at
large regional hospitals, stroke patients were
treated in medical wards, which I perceived as
a poor idea already as a young neurologist.
Neurologists are the ones who know the most
about the brain, just as cardiologists are the
ones who know the most about the heart.
PHOTO: Joachim ladefoged

24 Lundbeck Magazine 2009
"Unfortunately, there are
still major differences in the
treatment on offer to patients in
different countries in Europe"
Everyone agrees that patients with a
myocardial infarct should be treated by
cardiologists, but the attitude was that anyone
could treat stroke patients,” Markku Kaste says.
When he was able to document on the basis
of a study that stroke patients who had been
treated by neurologists were able to leave
hospital 16 days earlier than those treated in
other wards, and that more were discharged to
their own homes and were also better able to
care for themselves without help, the Helsinki
City Council saw the light. That happened in
1995. The stroke unit at HUCH Meilahti
hospital has since treated all acute stroke
patients in Helsinki. The experience gained in
acute care of stroke has been formulated as
European guidelines. The recommendations,
previously written by a task force of the
European Stroke Initiative (EUSI) and later on
by the European Stroke Organisation (ESO),
both of which Markku Kaste helped found, are
available in multiple languages.
Four out of ten neglected
“Unfortunately, there are still major differences
in the treatment on offer to patients in
different countries in Europe. Recently we
asked 4261 randomly selected hospitals
throughout the EU about their treatment of
stroke, and the results were shocking. Only one
out of seven patients – between 13 and 14 per
cent – were treated as recommended by WHO
i.e. in a stroke unit at a university hospital or
other well equipped hospital, which has
neurologists, cardiologists, neurosurgeons,
vascular surgeons, and a CT scanner that is
manned 24 hours a day. Forty-four per cent
receive acceptable treatment, generally at
large hospital centres. But the remaining 42
per cent are treated in hospitals that lack both
equipment and experience. And this happens
in rich countries as well as in poor. This is not
only appalling for patients, it is also costly for
society,” Markku Kaste says.
Too weak to bang on the table
Stroke is an illness which costs society a lot
of money. “In Finland, caring for a patient in
a nursing home costs EUR 50,000 per year.
As strokes generally occur in persons between
the ages of 60 and 70, their life expectancy is
higher than, for example, persons with
dementia, who are usually older when they
enter a nursing home. Stroke is exceedingly
expensive for society, but those who have
suffered a stroke are too weak to bang on
the table and demand better treatment. This
makes it important to prevent the illness –
also from an economic point of view,”
Professor Kaste continues.
The factors that can cause stroke are the same
as those that can cause cardiovascular
diseases: high blood pressure, high cholesterol,
obesity, smoking, high alcohol consumption
and lack of physical exercise.
Quick treatment makes the difference
“It is therefore possible to do something
oneself, and prevention is of course the best
mode of action. But for those who suffer a
stroke anyway, it is important for society to
invest in stroke units where it is possible to
obtain the best possible treatment, which
increases the likelihood of good recovery. With
the present drugs for dissolving blood clots, we
consider it possible to save many patients up
until four and a half hours of the time of the
symptom onset and in some patients even
after longer time before irreversible damage
occurs. We are currently investigating a new
drug which may give us as much as nine hours,
and thus more time to get patients to
hospitals that can provide the right treatment.
Some patients cannot tolerate drugs that solve
the blood clot, which occludes the brain artery,
for example if they have very high blood
pressure or internal bleeding. But quick arrival
at the hospital and appropriate treatment
benefit all patients. Competent intervention by
a wide spectrum of specialists reduces the risk
of the patient dying or becoming helpless and
requiring care. Quick and correct treatment is
good for the individual patient, and a major
economic benefit for society,” says Professor
Markku Kaste.
PHOTO: Joachim ladefoged

Lundbeck Magasinet 2009
25

26
"I have been involved all the
way from oldfashioned
psychiatry to the present, and
a great deal of progress has
been made during that time"
Sales rep Thorfinn Nygård drives 50,000 km per year
on the roads in northernmost Norway.

Lundbeck Magazine 2009
27
A laptop
and a vacuum flask
Throughout his 14 years as a sales rep for Lundbeck Norway,
he has been braving snowstorms and high water to reach
doctors and give them the most recent knowledge on
psychiatric disorders and the possibilities of treating them.
In the village in Norway where Thorfinn
Nygård grew up in the years after WWII, there
was a special way of expressing that someone
had been admitted to hospital with a
psychiatric disorder. When someone had been
led to hospital, it was understood that it might
be some time before one saw the person again.
Indeed, one might never see them again.
Since then, the possibilities of treating these
disorders have improved a great deal. And
Thorfinn has contributed to people in all of
northern Norway being able to obtain help if
they become affected by a psychiatric
disorder.
Largest district
Thorfinn travels 50,000 km a year in his 4WD,
accompanied by a vacuum flask of hot coffee
and music or reading on the CD player. And
this does not include air travel and trips in
hired cars.
“I visit doctors in an area stretching from just
south of Trondheim to Narvik in the north, a
distance of nearly 1200 km. No other reps
cover such a large area, and it is necessary to
be well acquainted with both the district and
ferry schedules to keep one’s appointments.
Otherwise, one won’t be in the right place at
the right time,” says Thorfinn, who over the
year is in contact with approximately 1000
GPs as well as a number of specialists.
He sees working with doctors as a form of
collaboration.
“I don’t have a single pill in my briefcase, only
information. My most important sales tools
are myself and my laptop. Every day is a
challenge, because doctors are busy and it can
be difficult to engage them in conversation.
Many of my appointments take place during
doctors’ lunch hour, so I take food along, and
then the doctor has time to chat. I have known
some of the doctors for decades, and that is an
advantage. Personal acquaintance means a
lot,” Thorfinn says.
Major progress
He has observed developments in psychiatry
at close hand for more than 40 years, ever
since he was employed as a carer at a
psychiatric hospital in 1968. Thorfinn later
became a nurse, leaving the public health
system in 1988 for a job in the pharmaceutical
industry at a Danish company then known as
Dumex. He was headhunted by Lundbeck
Norway in 1995.
“I have been involved all the way from oldfashioned
psychiatry to the present, and a
great deal of progress has been made during
that time. When the first neuroleptics were
introduced in the 1950s, it emerged that very
little was known about either the medications
themselves or correct doses. The drugs were
simply given to patients until their skin turned
yellow. Then the organism was saturated and
reduction could begin. The side effects were
severe. The patients were exhausted, and the
medication affected their cognitive abilities.
Today, we fortunately have drugs with far
fewer side effects,” Thorfinn states.
Among the eldest
He has long since celebrated his 60th birthday,
and is thus one of the eldest Lundbeck sales
reps. But Thorfinn is not finished with life on
the steep and crooked roads.
“For me, working with a company that has
helped improve treatment of persons with
psychiatric disorders has been very fulfilling.
I have seen what it was like before – how few
options were available. This is what drives me
forward and keeps me going,” Thorfinn
remarks.
PHOTO: Simon ladefoged

28 Lundbeck Magazine 2009
A career
with global focus
Her career with Lundbeck has to date led Italian-Canadian
Lorena Di Carlo across the Atlantic from Montreal to
Copenhagen, and then down under to Sydney.
Lorena Di Carlo had only been with Lundbeck
Canada as a CNS Specialist for six months
when she took on the role of Associate
Product Manager with responsibility for the
nation-wide launch of Celexa®/Cipramil®. The
ensuing launch became the most successful
introduction of a new antidepressant on the
Canadian market, with Lundbeck Canada
experiencing almost explosive growth.
“We were 10 employees when I was hired in
1995, and 140 a couple of years later,” Lorena
recalls, admitting that she knew only very little
about Lundbeck when she was hired and met
with the words: “Welcome to Lundbeck. You’re
our first staff member in North America.” At
that time she had been working three years in
sales. Lorena was enthusiastic about being part
of the founding team of a new company in
Canada whose mission is to improve the
quality of life of people with psychiatric and
neurological disorders. Her career took off
immediately, and she became Vice President of
Marketing at Lundbeck Canada before her
career led her to Denmark and, most recently,
to Sydney in Australia.
Lundbeck gave me the chance
“The values first led me to Lundbeck and has
kept me with the company over the years –
primarily because being imaginative,
responsible and never giving up are values that
are entirely compatible with my own. I am very
result oriented and I am fully committed to
PHOTO: Simon ladefoged

Lundbeck Magazine 2009
31
"Experience has taught me not to
engage in comparisons of how things are
done ‘at home’. Being openminded and
appreciative is the best approach"
Lundbeck’s vision of being the world leader
in CNS. My contribution has always been
appreciated and I really do feel that as part
of a wider team, I am helping to make a
difference. In addition, there is the willingness
to take a chance. Lundbeck took a chance with
me by giving me the opportunity to launch
Celexa®/Cipramil® early in my career, and I
appreciate that.”
Since then, Lundbeck has become an
international company with 55 subsidiaries
around the world.
“Lundbeck has progressed from having a
mainly European focus to being an
international company, and is well on its way
to becoming a global leader in CNS. What I
value most about the scope of my role is that,
on the one hand, I know each and every one of
my reps, and as a subsidiary we have room for
flexibility and individual ideas. On the other
hand, I have colleagues all over the world, and
am constantly aware of our global focus,” says
Lorena, who holds a Degree in Marketing and
an MBA in International Business. She was also
a member of the Strategic Marketing Team for
six months in Valby and is a long-time member
of the Global Brand Board which meets twice a
year to provide input on global marketing
initiatives. She is now located on the other
side of the globe in Sydney where she has
been Sales and Marketing Manager of
Lundbeck Australia for one year.
Tri-cultural
“Having grown up in French-speaking Montreal
with Italian parents, I am naturally tri-cultural,
so I find it easy to adapt to new cultures. And
even though Australia is a Western culture,
there are still many nuances. Experience has
taught me not to engage in comparisons of
how things are done ‘at home’. Being openminded
and appreciative is the best approach.”
Lorena likes living down under, where she
heads a group of some 60 staff members.
“Australia is a very interesting market. It is very
thoroughly regulated and has lots of obstacles,
but once one gains a foothold, it is very
attractive. Lundbeck is well regarded by
physicians, and Australia is among the largests
markets for Lexapro®/Cipralex®, despite the
fact that the country has only 21 million
inhabitants.”
Global network
Thanks to her Lundbeck network, Lorena had
friends in Australia from the day she arrived.
“After almost 15 years with Lundbeck, I have
an extensive network all over the world.
Professionally, it is fantastically beneficial to
be able to phone a colleague in Spain to learn
how they have solved a problem, but it is also
personally rewarding. People have a tendency
to stay with Lundbeck, and colleagues turn
into friends.”
“I really enjoy the Australian outdoor culture.
I run, I recently started cycling, and I have a
swimming coach. My aim is to do a triathlon
before the end of the year. I ran my first
marathon in Chicago 18 months ago. Apart
from that, I have also tried surfing, but after
the shark attacks of recent months, I may well
decide to relent on my motto: never give up!”
How long do you intend to stay in Australia
before you move on in your career?
“I will certainly stay until I finish my
assignment. What happens after that will
depend on where my skills are best suited and
needed,” Lorena replies with a smile. “I am
open to anything that will contribute to the
company’s success and help me continue to
develop and learn, no matter where in the
world it might be.”
PHOTO: Simon ladefoged

32
Danish-Japanese partnership
– the American way
Antidepressants of the future are being developed jointly
by Lundbeck and Takeda Pharmaceutical Company.

Lundbeck Magazine 2009
33
In 2007, Lundbeck entered into a strategic
alliance with Takeda, Japan’s largest
pharmaceutical company. The partnership
involves further development of a new series
of compounds for treatment of disorders such
as depression and anxiety, as well as marketing
of the finished drugs in Japan and the United
States.
The substances, which were discovered by
Lundbeck, belong to a totally new
pharmacological class of drugs. It is expected
that these drugs will be superior to current
antidepressants in a number of areas.
Researchers from Lundbeck in Denmark are
participating in the development activities,
together with Takeda’s US subsidiary, Takeda
Global Research & Development Center, Inc.
located at Deerfield, Illinois, near Chicago.
At least once a month, Marianne Dragheim,
Senior Specialist and Medical Doctor, boards
an aeroplane for Chicago to meet with her
colleagues at Takeda. Marianne is in charge of
the clinical aspects of the project at Lundbeck,
and sees clear advantages in the alliance with
our Japanese partner.
Ambitious plan
“Without our partnership with Takeda, we
would not have advanced to the current stage.
Lundbeck would not have been able to do it
alone, as we have neither the resources nor the
necessary staff. Lundbeck has the know-how
and Takeda has the resources for developing
drugs to treat disorders of the central nervous
system. This is why companies form strategic
alliances; a company needs a partner to help
bear part of the burden. We have had a clear
vision of what we want to do from the very
beginning – and a very ambitious schedule for
the project. I think Takeda thought we were
a bit mad when we first showed it to them,”
Marianne says.
Amazed and fascinated
Atul Mahableshwarkar, Senior Medical Director
with Takeda and psychiatrist by training, is in
charge of the clinical aspects of the project.
He, and others were hired by Takeda to work
with Lundbeck on this project. Atul clearly
remembers his initial reaction on being
introduced to it for the first time.
“I was amazed at both the scope and the
time horizon, but now I am fascinated by
how well it has gone. Merely developing an
antidepressant for multiple indications –
depression and anxiety – at the same time is
new and has not been done simultaneously
before. In fact, one of our key opinion leaders
has suggested that we publish a report on our
work, once the substances are on the market,
because this is something we can be proud of,
and it can be used as an example of how to do
things correctly,” Atul says.
Learning from each other
Transatlantic collaboration requires planning,
but it is worth the effort, he believes.
“We come from our own two cultures, so we
approach things in different ways. Our various
backgrounds enhance our perspective of
developing pharmaceuticals. One of the major
benefits of our collaboration is being able
to draw on our wide ranges of experience.
Lundbeck has developed many other drugs
for use in the CNS field. Takeda's contribution
is our experience in developing drugs in
the United States. In addition to my drug
development experience, I personally have
treated thousands of persons for depression.
Moreover, Lundbeck and Takeda both have
experience in their various markets.
Registering a drug with the U.S. Food and
Drug Administration (FDA) is different than
registering with the European Medicines
Agency (EMEA). We learn from each other
all the time, and I have benefited from working
with my Lundbeck colleagues. Of course there
are challenges in combining two different
corporate cultures and ways of working, but we
have a common goal of which we are aligned
around,” Atul states.
Mutual values
Lundbeck and Takeda are jointly responsible
for the project.
“All decisions are made jointly, and we must
always concur in major decisions. Working
together also enables us to use our resources
better. And while we are pressed for time,
everyone is very committed and in total
agreement on the goal. Not all companies are
like that, but Lundbeck and Takeda are similar in
this respect. There are people on both sides of
the Atlantic who have been working very hard
for a very long time. This is true of everyone
who is involved in the project, not just the front
figures. Staff members grow with a project
when they are included the way they are at
both Takeda and Lundbeck,” Marianne says.
Looking forward to approval
She thrives under pressure.
“I am happiest when all the odds are against us.
But if I had to do it again, I would probably try
to ensure that we had more of the necessary
resources,” says Marianne.
Atul is looking forward to seeing the first
substances approved as drugs in Europe and the
United States during the coming years.
“And I would be incredibly happy if I sometime
in future – perhaps 15 years from now – could
say that millions of people’s lives are better
because of the work we have done together.
That is my motivating force,” says Atul.
PHOTO: Joachim ladefoged

Lundbeck Magazine 2009
35
Tommy Skovby is a chemical engineer at the Lundbeck
synthesis factory at Lumsås where he chairs a project that is
to prepare the way for an entirely new way of manufacturing
pharmaceuticals.
As the author of a dissertation on aromatics for
use in the food industry, Tommy Skovby’s
education actually prepared him for a different
line of work. But ever since he began working in
the Quality Department at the Lumsås factory
nine years ago, he has focused on production of
pharmaceuticals. Tommy is deeply involved at
present in a project that, in the foreseeable future,
will change pharmaceutical production as we
know it.
The current method of manufacturing drugs is on
the way to being replaced by a new process which
is fundamentally different, and Lundbeck is at the
forefront of developments.
Known as continuous production, the method is
new to the pharmaceutical world, though it has
for many years been used by refineries and
chemical industries. Instead of producing large
amounts of a product in batches and closing
down the production line between each batch,
the new method involves manufacturing only
small amounts on a production line that is in
continuous operation. The process is monitored at
strategic points along the way, enabling errors to
be isolated. An entire production system takes up
only a fraction of the space required for current
systems, and is also cheaper and safer for
employees to operate.
Financial necessity
Small-scale continuous production saves money
in several ways, such as power bills.
“With our current method, we heat up a steel
reactor weighing a couple of tons and then cool it
down again several times during a production
process. In future, we will achieve the same result
with a small steel box at only a fraction of the
cost. The systems are so small that it is possible to
have 10 reactors in a space the size of a family
sitting room. A system of this kind saves money
on both heating and ventilation, and we will be
able to increase production tenfold without
moving a single wall,” Tommy says. Financial
necessity is a significant reason for introducing
continuous production.
“At Lundbeck we annually manufacture between
30 and 40 tons of escitalopram, the active
ingredient in Cipralex®. Production takes place in
reactors large enough to contain between 3000
and 4000 litres, and each batch must be put into
sacks or barrels and moved to a warehouse where
they occupy space. If we switch to continuous
production and manufacture 60 grams per
minute, the process can take place in a space
roughly the size of a matchbox,” Tommy explains.
Globalization has added further pressure to keep
production costs down.
“Ten years ago we manufactured most of the raw
materials ourselves, whereas we now purchase
them in the Far East. We must consider how we
can reduce our costs, and it’s a matter of reducing
them as soon as possible,” Tommy continues.
Extremely interesting
As Senior Project Manager, he heads a project
known as Innovative Future Manufacturing IFM.
“When I began working here, I flirted a bit with
process intensification, in which technologies are
combined to improve processes. It was in reality
the forerunner of continuous production, so, in
that sense, I have led the project from the very
beginning – though not full-time. Our main job at
Lundbeck is to manufacture, so the project has
been put on hold several times along the way. In
2006, we devised a strategy for tackling
globalization, and the continuous production
project is part of that strategy,” explains Tommy,
who has been an ardent supporter of the new
method all along.
“Someone had to champion the cause, and it
happened to be me. Both because it is extremely
interesting for an engineer from a professional
point of view, and because, in the final analysis,
it is a matter of Lundbeck’s production activities
surviving in the long term. That is my driving
force,” Tommy states.
Collaboration with the Technical University
of Denmark
The actual systems for the project are one of the
major challenges. They cannot be bought, but
must be developed from scratch. Lundbeck has
therefore entered into a five-year agreement
with DTU concerning development of
applications for the new production method.
Several students are involved in designing
proposals, and the first results have already been
presented for Lundbeck.
“The aim of collaborating with DTU is to obtain
a number of building blocks to have at our
disposal. Everyone in the pharmaceutical
industry is interested in the possibilities, but not
many dare experiment with it. It is difficult to
break the habit of batch production, because it
has been the basis for manufacturing in the
pharmaceutical industry for so many years,”
Tommy says. “Lundbeck would like to be a
pioneer in the area.”
“But we aren’t in any rush. The project has been
set in motion because Lundbeck can see a
number of advantages in the method. And we
aren’t in a great hurry; we would prefer to reap
the results gradually as we move forward,”
concludes Tommy.
PHOTO: Simon ladefoged

Lundbeck Magazine 2009
37
Always
one step ahead
The tempo has been high at Lundbeck Turkey since Gaye
Burhanoglu became Managing Director seven years ago.
If Gaye Burhanoglu were to identify her
greatest fault, it would perhaps be her inability
to sit down and do nothing for five minutes at
a time. However, this trait is also one of her
greatest strengths, because it ensures that she
and Lundbeck Turkey are always one step
ahead of competitors in a country where
everything takes place at a hectic pace. It is
likewise one of the reasons why Lundbeck is
number one in CNS in Turkey and why
Cipralex® is clearly the market leader in
antidepressants.
And while Turkey is also feeling the effects of
the world economic crisis, there are no signs of
a crisis at Lundbeck in Istanbul, where the
headquarters have just moved to new and
larger offices and added 10 new reps to the
staff, bringing it up to 170 in all.
Gaye has been with Lundbeck Turkey from
its very beginning in 2000 when she was
headhunted for the job as Sales and Marketing
Manager from a post as head of the CNS
business unit at Novartis. Eighteen months
later she took over the reins as Managing
Director of Lundbeck Turkey.
“CNS has always been very close to my heart.
Indeed, one might say that it has become my
destiny. I have always been deeply interested
in the human psyche, and I find associating
with CNS specialists intellectually enriching.”
Cotton and olives
Gaye has a degree in marketing from one of
the most prestigious universities in Istanbul.
Her mother is a gynaecologist, and even
though Gaye can clearly recall sales reps
calling at the family home when she was a girl,
it was definitely not in the cards that she
would end up working in the pharmaceutical
industry.
“I thought I wanted to be a farmer and grow
olives and cotton on my family’s property in
southwest Turkey,” says Gaye who was born
and raised in Izmir.
On finishing school, she moved to Istanbul to
study at the School of Agriculture, but changed
her mind and opted for marketing instead.
Since then she has lived in Istanbul, a city of
approximately 20 million inhabitants. The
exact population of this city situated at the
crossroads of Europe and Asia is unknown, as
thousands of the country’s 70 million citizens
flock to the metropolis every day in search of
prosperity.
"Turkey is a very dynamic country with a
young population that is eager to attempt
new things, and I love that attitude"
Fought and won
“Turkey is a very dynamic country with a
young population that is eager to attempt new
things, and I love that attitude,” Gaye says.
However, rapid developments – not least in
Istanbul – are also an enormous challenge for
Gaye and the staff members at Lundbeck
PHOTO: Simon ladefoged

38 Lundbeck Magazine 2009
"I have always been deeply
interested in the human psyche,
and I find associating with CNS
specialists intellectually enriching"
Turkey, because the market changes from day
to day.
“This means that we must constantly be a
step ahead of everyone else. From the very
beginning, I fought for more reps because it
suddenly became possible to market Cipramil®
directly to GPs. We were only 15 employees at
the time, and I could see opportunities in
expanding our staff. We succeeded in
convincing headquarters, though it took some
time,” says Gaye, who found it difficult to
maintain her patience. Her efforts paid off in
the end, however, with sales of Cipramil®
rocketing skyward and becoming the bestselling
pharmaceutical in Turkey in 2003.
Cipralex® has since taken over the role of
market-leading antidepressant in Turkey.
Despite keen generic competition, sales are
still rising.
Cipralex® has six generic copies. There are four
of Ebixa®. However, they are branded generics
which cost 80 per cent of the price of the
originals. Under the current health system and
reimbursement regulations, only a fraction of
patients must pay for treatment with the
original products.
“In terms of pharma, Turkey is close to being
on a par with Europe. Regulations have
become more and more stringent, and the
government is taking longer and longer to
process applications for price adjustments and
reimbursement. This will result in major
challenges for us in the time ahead,” says
Gaye, who has handled numerous crises over
the years. In her view, she merely needs to
apply an extra large amount of her
competitive gene and combat capability.
Loves sports
She cultivates both by engaging in a variety of
sports in her spare time. “I love sports. I used
to swim when I was young, and I played
basketball at a professional level. Basketball
taught me teamwork and swimming taught
me self-discipline. Both are useful in my work.
I now have very little spare time, but we have
a gym at the office where I do Pilates. I also do
yoga, and we compete in Wii Sports in my
family at home.”
Gaye is the mother of two daughters aged 20
and four, hence her lack of spare time.
“With my first daughter, I was so busy that
time just flew by, but I now have another
perspective on life and try to maintain a better
balance between my work and my private life.”
To the extent that time allows, she travels the
world with her husband who has his own
company and is a passionate photographer.
“As I mentioned, I find it difficult to sit still for
very long at a time,” Gaye says with a smile.
“I do feng shui to acquire more peace and
harmony – also here at the office. I used the
principles when we furnished our new offices,
and when I eventually retire, I may well begin
working as a feng shui consultant. I could
never even dream of stopping work entirely.”
PHOTO: Simon ladefoged

40
From genes
to galaxies
The Lundbeck Foundation is one of Denmark’s largest private
contributors to research in the health and natural sciences.

Lundbeck Magazine 2009
41
s an active researcher, Anne-Marie
Engel was so successful at applying
for and obtaining financing for her
research that she taught her colleagues how
to write applications that get the desired
results. Now, she is on the other side of the
table. As Director of Research at the Lundbeck
Foundation and secretary of its selection
committee, Anne-Marie Engel is involved in
processing the approximately 600 applications
for funds for research purposes in the health
and natural sciences which the Foundation
receives annually.
The selection committee has eight members,
three of whom are on the board of the
Lundbeck Foundation, and three of whom are
scientific experts in Denmark’s neighbouring
countries. The eight members gather three
times a year to assess the individual
applications, in order to provide the best
possible basis for the Board of the Lundbeck
Foundation to distribute the large amounts
of money at its disposal. Between 2008 and
2010, the Foundation will distribute
approximately DKK 1 billion.
Many excellent researchers
The first requirement is that research must be
top quality, a criterion that applicants normally
have no difficulty in meeting.
“We see many good applications, and it is
my impression that we have many excellent
researchers in Denmark. Research projects
must be in either the health or natural
sciences. The foundation has a long tradition
of supporting neurological research, though we
also give money to many other fields within
the health sciences. In recent years, we have
given money for research in areas such as cell
biology and cell communication. We have also
donated to translation, which deals with
building bridges between basic and clinical
research that is done with a view to
discovering improved methods of treatment
based, among other things, on new knowledge
of the role of genes in development of certain
diseases. If scientists can map the significance
of genes in development of illnesses such as
asthma and various life-style diseases, it will
have major consequences for both treatment
and prevention,” Anne-Marie Engel says.
Focus on intervention
Intervention is another area of current interest
to researchers.
“In 2008 we supported the establishment of
three centres. At the first centre, research is
being done to optimize radiation treatment
of various types of cancer, and at the second
centre efforts are being made to discover a more
efficient and less traumatic method of replacing
knees and hips. The third centre focuses on
neurological research, namely schizophrenia.
Danish scientists have helped establish the
existence of a chromosomal error that causes
susceptibility to schizophrenia – a discovery that
may well change the perception of persons with
psychiatric disorders – the same as discovery of
the bacteria that causes stomach ulcer has done
for persons with that disorder. These persons
used to be considered ‘delicate’. We now know
that the illness has a physiological cause,” Anne-
Marie Engel continues.
A few years ago, the Board of the Lundbeck
Foundation also decided to earmark an amount
for research in physics and chemistry, and the
Foundation has also given money to projects
such as Danish scientists’ studies of the universe.
“It is very difficult to obtain financing for this
type of research in Denmark, while there are
many foundations that support research in the
health sciences. The Lundbeck Foundation
wishes to support Danish research on a broad
front. We believe it is important to have a
dynamic research environment in Denmark,”
states Anne-Marie Engel.
Too few young people
She is a medical doctor, and became
fascinated by research. She was employed as
a researcher at Statens Serum Institute when
she saw a job advert from the Lundbeck
Foundation. Much of the work consisted of
reading applications and writing an
introduction to them.
“It was the ideal job for me. I was always
reasonably lucky with writing applications to
foundations to finance my research. Later, I
taught others how to write successful
applications to foundations that had
previously turned them down,” Anne-Marie
Engel continues.
Her greatest concern for research is the fact
that too few young people are studying for
degrees in the natural sciences.
“It would be unfortunate if the falling
tendency continues. For this reason, the
Lundbeck Foundation is supporting a number
of initiatives that seek to influence students’
choice of field of study during their early years
at school. This must be done at a stage when
they are still asking spontaneous questions
about nature, and, among other things, the
initiatives involve strengthening instruction in
nature and technology for the youngest
children in primary schools. Teachers must
have more possibilities for making
experiments. Children love classes where they
are able to experiment, and they remember
them for a long time – perhaps for the rest of
their lives. Stimulating young people’s pleasure
in the natural sciences is very close to my
heart,” concludes Anne-Marie Engel.
The Lundbeck Foundation is a commercial foundation which was established in 1954 by Mrs Grete
Lundbeck, the widow of the founder of H. Lundbeck A/S. The primary aim of the Foundation is to
maintain and expand the activities of the Lundbeck Group, and to provide funding for research of the
highest quality in the health and natural sciences.
In 2007 and 2008, the Foundation supported the establishment of research centres whose aim is
to make the results of basic scientific research available for patients as quickly and efficiently as
possible. The theme for 2009 is nanomedicine.
In 2008, the Lundbeck Foundation donated DKK 328 million to research.
PHOTO: Joachim ladefoged

42 Lundbeck Magazine 2009
From idea
to drug
Distribution of drugs
Lundbeck drugs are registered in more than 90 countries.
Lundbeck’s own representatives are in charge of spreading the
knowledge of Lundbeck products in 55 countries. As Lundbeck
products are prescription drugs, doctors must decide when
patients will benefit from them. Lundbeck spreads knowledge
of its products through publications in scientific journals,
participation in scientific conferences, and through meetings
with doctors and specialists.
Production of drugs
A drug must be safe and efficacious. It must also be possible
to produce it in large amounts and in a manner that enables
patients to take the drug and assimilate it optimally in the body.
Lundbeck manufactures its own drugs in Denmark, the United
Kingdom and Italy where a total of 964 persons are employed in
the manufacturing. Lundbeck also collaborates with a number of
other companies on various phases of the production process,
ranging from supply of raw materials and semi-finished products
to pharmaceutical production and packing of the drugs.

Lundbeck Magazine 2009
43
700 million in the world
According to the World Health Organization (WHO), more than 700 million
cases of disorders of the central nervous system are reported each year. These
are serious and life-threatening illnesses that affect not only patients’ quality of
life, but also that of their families and friends. For society in general, the major
economic consequences caused by these conditions make it important to
develop new and innovative drugs. During the past 50 years, novel drugs have
revolutionized the possibilities of treatment. However, there is still a huge
unmet need for new and innovative drugs.
From idea to drug candidate
More than 480 persons are employed at the Lundbeck research
units in Denmark and the United States. The basis for a new and
innovative drug is deep insight into the disorder itself, and into the
unmet needs of patients. The process takes between three and five
years, during which researchers work to identify where in the
human organism a new drug must act and to test substances for
any efficacy, side effects and toxicity. If a substance passes all of
these tests, it becomes a drug candidate.
From candidate to approved drug
Lundbeck has development activities in some 40 countries around the world.
800 employees are involved in development activities which are necessary
for a drug to be approved. First, a substance is tested in healthy persons for
its tolerability, assimilation and distribution in the body. Following this, its
efficacy and side-effect profiles are tested in a small group of patients. In the
third and decisive phase, the drug is tested in a large group of patients.
Developing a new drug is very demanding, and normally takes between eight
and ten years.
ILLUSTRATION: MADS BERG

44 Lundbeck Magazine 2009
Lundbeck
Milestones
1945-1960
The foundation of Lundbeck’s CNS expertise
During the years following World War II, Lundbeck
intensified its research, laying the foundation stone
for the drugs which would later make Lundbeck
world famous. As the result of these efforts,
Lundbeck was able to introduce Truxal® in 1957,
one of the first drugs for treatment of
schizophrenia.
In 1954, Mrs Grete Lundbeck, the widow of
Lundbeck’s founder, established the Lundbeck
Foundation for the purpose of ensuring and
expanding Lundbeck’s business operations, as well
as for providing financial support for primarily
scientific objectives and fight against diseases.
1915-1930
The first years as a Danish trading company
Hans Lundbeck founded an agency in
Copenhagen on 14 August 1915. The company
dealt in everything from machinery, biscuits,
confectionery, sweeteners, cinema equipment
and cameras to photographic paper and
aluminium foil, besides renting out vacuum
cleaners.
During its first years, the business was operated
as a trading company, but, from the mid-1920s,
pharmaceuticals were added to its range of
products. Eduard Goldschmidt was hired in
1924, bringing into the company a number of
new agency contracts for drugs: suppositories
for haemorrhoids, painkillers etc. Cologne and
creams were also added to the portfolio.
1930-1945
Expansion in manufacturing and research
In the 1930s, Lundbeck began production and packaging
of pharmaceuticals in Denmark. To ensure sufficient
manufacturing capacity, the company moved to the
Copenhagen suburb of Valby in 1939, where Lundbeck
headquarters is situated today.
In 1937, Lundbeck introduced Epicutan® for treatment of
wounds – its first original pharmaceutical – and Lucosil®
for treatment of urinary tract infections in 1940. 45 staff
members celebrated Lundbeck’s 25th jubilee the same
year.
Hans Lundbeck died in 1943, and Poul Viggo Petersen was
employed to build up Lundbeck’s pharmaceutical research.
Thanks to his efforts, Lundbeck was able to create a niche
for itself in psychopharmaceuticals.

Lundbeck Magazine 2009
45
1975-1990
Lundbeck defines CNS as its primary focus
After 60 years of growth and development based on a
wide assortment of products, Lundbeck decided at the
end of the 1970s to phase out its existing agencies and
cosmetics departments. After that, the company would
focus on development and commercialization of drugs.
At the close of the 1980s, Lundbeck further intensified
its business strategy focus. In future, Lundbeck would
dedicate its efforts to development, manufacturing and
commercialization of drugs for the treatment of
diseases and disorders of the central nervous system.
Cipramil® was launched in Denmark in 1989 and
played a key role in Lundbeck’s expansion.
2005-2020
Best CNS company
In 2009, Lundbeck has more than 5,500 staff
members who work in 55 countries. Lundbeck has a
broad portfolio of drugs on the market for treatment
of depression, anxiety, schizophrenia, Alzheimer’s
disease and Parkinson’s disease. Lundbeck has 12 new
and innovative drugs under development.
Lundbeck’s ambition is to be the worlds best
company in development of drugs for treatment of
disorders and diseases of the central nervous system.
With more than 50 years of experience in
development and commercialization of CNS drugs,
Lundbeck has a solid foundation for ensuring that this
ambition can be fulfilled during the coming decade.
1960-1975
Expanding Lundbeck goes international
Lundbeck’s success with Truxal® increased the
need for additional production capacity. In 1961,
Lundbeck purchased a redundant creamery in
Lumsås and soon began production of active
compounds.
A number of drugs for treatment of psychiatric
disorders were launched during the following
years, and Lundbeck established its own
representation in a number of countries. Between
1960 and 1970, the number of employees
doubled to 680, of whom approximately 100
were employed abroad. Lundbeck was becoming
an international company.
1990-2005
Expansion propelled by Cipramil® success
Lundbeck expanded rapidly in the 1990s, due to the success of Cipramil® for
treatment of depression. Cipramil® was registered in more than 70 countries and
grew to account for the major share of Lundbeck’s business operations.
To ensure its continued success, Lundbeck intensified its research activities and
began in-licensing drugs from other pharmaceutical companies. This enabled
Lundbeck to launch new drugs to take over when the patent on Cipramil® expired.
Cipralex® was launched in 2002 and Ebixa® in 2003, and the two drugs were
capable of compensating for Cipramil® when it was exposed to generic
competition.
In 2003, Lundbeck acquired the American research company Synaptic, thereby
establishing an American research unit as a bridgehead in the United States.

46 Lundbeck Magazine 2009
Lundbeck
at a glance
H. Lundbeck A/S is an international pharmaceutical company with more than 50 years of experience
in research, development, production, marketing and sale of pharmaceuticals for the treatment of
diseases of the central nervous system, CNS.
Our values
Imaginative – Dare to be different
Passionate – Never give up
Responsible – Do the right thing
Founded in 1915 by Hans Lundbeck, the company
was listed on the Nasdaq OMX Copenhagen stock
exchange in 1999.
The Lundbeck Foundation is the largest shareholder,
own-ing about 70% of the shares. In 2008, the
foundation paid out DKK 328 million in funds for
scientific research.
Lundbeck worldwide
The Group employs more than
5,500 employees in 55 countries.

Lundbeck Magazine 2009
47
Cipralex/Lexapro® (escitalopram)
Approved for:
Depression and anxiety
Launch year:
2002
Partner:
Forest Laboratories, Inc. (USA)
Azilect® (rasagilin)
Approved for:
Parkinson’s disease
Launch year: 2005
Partner:
Teva Pharmaceutical
Industries Ltd.
Ebixa® (memantin)
Approved for:
Alzheimer’s disease
Launch year:
2002
Partner:
Merz Pharmaceuticals GmbH
Serdolect® (sertindol)
Approved for:
Schizophrenia
Launch year:
2006
Circadin®
Approved for:
Insomnia
Launch year:
2008
Partner: Neurim
Pharmaceuticals Ltd.
Revenue per product 2008
16%
1%
2%
14%
22%
2%
43%
Cipralex®
Lexapro®
Ebixa®
Azilect®
Serdolect®
Other
pharmaceuticals
Other revenue
Revenue DKK 11,282 million
Research and development costs DKK 2,992 million
Profit from operations DKK 2,352 million
Net profit for the year DKK 1,510 million
Pharmaceuticals in clinical development
Development stage Registration
Indication I Compound Phase I Phase II Phase III application
Employees by business area 2008
2,500
2,000
1,500
1,000
500
0
Production
Research & Sales &
development marketing
Europe USA Other
Administration
Schizophrenia I Serdolect® USA
Depression/angst I Lu AA21004 2010
Schizophrenia I Bifeprunox 2011
Alchol dependence I Nalmefen 2011
Stroke I Desmoteplase 2011+
Psychosis I Lu 31-130 2011+
Depression I Lu AA24530 2011+
Depression/bipolar disorder I Lu AA34893 2011+
Psychosis I Lu AE58054 2011+
Psychosis/bipolar disorderI Lu AA39959 2011+
Stroke/neuronal damage I Lu AA24493 2011+
Neurological diseases I Lu AA38466 2011+

The specialist in psychiatry
and pioneer in neurology
H. Lundbeck A/S
Ottiliavej 9
2500 Copenhagen - Valby
Denmark
Corporate Reporting
Tel +45 36 30 13 11
Fax +45 36 30 19 40
information@lundbeck.com
www.lundbeck.com
CVR no. 56759913